India Approves First Homegrown Covid Vaccine For Children Aged 12 To 18
Bharat Biotech's COVAXIN Vaccine Gets nod of India's Drug Regulator
The DCGI has approved the use of Bharat Biotech's COVAXIN vaccine for children aged 12 to 18, making it the first homegrown vaccine to receive approval for use in this age group.
The decision was taken at a meeting of the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday. The SEC had previously recommended the vaccine for restricted use in children aged 12 to 18 after reviewing data from clinical trials.
COVAXIN is a whole-virion inactivated vaccine, which means that it contains the entire SARS-CoV-2 virus that has been inactivated, or killed, so that it cannot cause disease. The vaccine is administered in two doses, 28 days apart.
The approval of COVAXIN for use in children aged 12 to 18 is a significant step in India's fight against the COVID-19 pandemic. The vaccine is expected to play a major role in protecting children from the virus and helping to control the spread of the pandemic.
In addition to COVAXIN, there are several other COVID-19 vaccines that are currently being evaluated for use in children. These include the Pfizer-BioNTech vaccine, the Moderna vaccine, and the Johnson & Johnson vaccine.
The approval of COVAXIN for use in children aged 12 to 18 is a positive development in the fight against the COVID-19 pandemic. The vaccine is expected to play a major role in protecting children from the virus and helping to control the spread of the pandemic.
Rs Virus Vaccine
Komentar